Evidence map›Paper›PMID 42670789›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2026

Comparative Prognostic Impact of Two-Dimensional and Three-Dimensional Computed Tomography-Based Sarcopenia Indices in Metastatic Castration-Sensitive Prostate Cancer.

Tomohiro Hori, Hiroaki Iwamoto, Takahiro Inaba, Ryunosuke Nakagawa, Taiki Kamijima, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Suguru Kadomoto, Hiroshi Yaegashi and 4 more

Abstract readComparative Study
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tomohiro HoriDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0009-0005-0355-1005
Hiroaki IwamotoDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-3599-2217
Takahiro InabaDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0009-0002-9449-5421
Ryunosuke NakagawaDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-2503-8908
Taiki KamijimaDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0009-0003-2553-0497
Hiroshi KanoDepartment of Urology, Komatsu Municipal Hospital, Komatsu, Japan.ORCID https://orcid.org/0000-0002-3543-1236
Tomoyuki MakinoDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-2554-7048
Renato NaitoDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-3936-7235
Suguru KadomotoDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-4136-8998
Hiroshi YaegashiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-3188-8834
Kazuyoshi ShigeharaDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-2118-9135
Takahiro NoharaDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0001-9792-2068
Kouji IzumiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-8480-9100
Atsushi MizokamiDepartment of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.ORCID https://orcid.org/0000-0002-5643-2182

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study evaluated and compared the prognostic significance of three different computed tomography (CT)-based radiological indices of sarcopenia-skeletal muscle index (SMI), psoas muscle index (PMI), and three-dimensional (3D) psoas muscle volume index (PVI)-in patients with metastatic castration-sensitive prostate cancer (mCSPC).

methodsWe retrospectively reviewed 120 patients diagnosed with mCSPC (2003-2022). Baseline muscle parameters were calculated from diagnostic CT scans. Sarcopenia was defined using the Martin criteria for SMI, and optimal cut-offs derived from maximally selected rank statistics for PMI (4.08 cm

resultsAdvancing age was significantly associated with SMI (OR: 1.05, p = 0.036) and PVI-defined sarcopenia (OR: 1.09, p < 0.001), with a non-significant trend for PMI (OR: 1.06, p = 0.069). Survival analysis revealed that sarcopenia by all three indices was significantly associated with worse OS (SMI [HR: 1.88, p = 0.032], PMI [HR: 2.19, p = 0.016], and PVI [HR: 2.07, p = 0.013]). In multivariable analyzes, SMI (HR: 1.86, p = 0.042), PMI (HR: 3.73, p < 0.001), and PVI (HR: 2.46, p = 0.006) remained independent risk factors for poorer OS. No significant impacts were observed for PCSS.

conclusionsWhen using body physique-adjusted or mathematically optimized thresholds, all three easily and rapidly measurable radiological indices (SMI, PMI, and PVI) may serve as potential, independent prognostic indicators for OS in patients with mCSPC.

Indexed as

Prostatic NeoplasmsPsoas MusclesSarcopeniaTomography, X-Ray ComputedAgedAged, 80 and overAge FactorsHumansImaging, Three-DimensionalMaleMiddle AgedPrognosisRetrospective Studiesprognosisprostatic neoplasmssarcopeniasurvival analysisX‐ray computed tomography

Identifiers

PMID42670789
PMCPMC13527747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.